Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $3.90 to $4.34
• 50-Day Range: $3.92 to $5.20
• 52-Week Range: $3.11 to $9.54
• Volume: 145,947 shs
• Average Volume: 114,979 shs
• Market Capitalization: $116.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Telomir Pharmaceuticals Stock Analysis - MarketRank™

Telomir Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 627th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Telomir Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Telomir Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Telomir Pharmaceuticals is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telomir Pharmaceuticals is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telomir Pharmaceuticals has a P/B Ratio of 195.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.48% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently decreased by 2.29%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telomir Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telomir Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.48% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently decreased by 2.29%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.40

News Sentiment

Telomir Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Telomir Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

TELO Stock Analysis - Frequently Asked Questions

How have TELO shares performed this year?

Telomir Pharmaceuticals' stock was trading at $4.12 on January 1st, 2025. Since then, TELO shares have decreased by 5.1% and is now trading at $3.91.
View the best growth stocks for 2025 here.

How were Telomir Pharmaceuticals' earnings last quarter?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced its earnings results on Tuesday, February, 4th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05.

When did Telomir Pharmaceuticals IPO?

Telomir Pharmaceuticals (TELO) raised $7 million in an IPO on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments acted as the underwriter for the IPO.

Who are Telomir Pharmaceuticals' major shareholders?

Telomir Pharmaceuticals' top institutional investors include Geode Capital Management LLC (1.39%), Northern Trust Corp (0.51%), Bank of New York Mellon Corp (0.24%) and Charles Schwab Investment Management Inc. (0.16%).

How do I buy shares of Telomir Pharmaceuticals?

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/04/2025
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CUSIP: N/A
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (737)-289-0835
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +283.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,530,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,170.58%
• Return on Assets: -832.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 195.50

Miscellaneous

• Outstanding Shares: 29,760,000
• Free Float: N/A
• Market Cap: $116.36 million
• Optionable: N/A
• Beta: N/A